Moxifloxacin

Generic name
Moxifloxacin
Brand name
ATC Code
S01AE07
Compare …

Moxifloxacin

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Bacterial conjunctivitis
  • Ocular
    • 1 month up to 18 years
      [1]
      • In the affected eye: 1 drop(s)/dose 3x daily.
      • Duration of treatment:

        The infection should usually improve within 5 days. The treatment must then be continued
        for a further 2-3 days

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Very few details are available about the efficacy and safety when used in neonates. Because the data is insufficient, use in eye infections with Chlamydia trachomatis in children aged < 2 years is not recommended.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTIINFECTIVES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Antibiotics
S01AA26
S01AA11
S01AA24
S01AA12
Antivirals
S01AD03
ANTIBIOTICS
S01AA26
S01AA11
S01AA24
S01AA12
ANTIVIRALS
S01AD03
Fluoroquinolones
S01AE01

References

  1. Alcon Nederland BV, SPC Vigamox (RVG 102202) 31-3-2016, www.geneesmiddeleninformatiebank.nl
  2. Bayer Int, DHPC Fluorochinolonen, 29 maart 2019
  3. BfArM., Rote-Hand-Brief zu Fluorchinolon-Antibiotika. 08.04.2019. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2019/rhb-fluorchinolone.pdf;jsessionid=4D7FF38A3DCDA1F9795930B56FD1B5E8.2_cid329?__blob=publicationFile&v=3, zuletzt aufgerufen am 12.04.2019.

Changes

Therapeutic Drug Monitoring


Overdose